You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report
|
|---|---|
| Published in |
BMC Cancer, December 2013
|
| DOI | 10.1186/1471-2407-13-618 |
| Pubmed ID | |
| Authors |
Angelika Bezan, Florian Hohla, Thomas Meissnitzer, Richard Greil |
| Abstract |
Catumaxomab, the first anti-EpCAM antibody, was approved in 2009 for the treatment of malignant ascites in cancer patients with EpCAM positive tumors. We consider this case of interest as treatment with catumaxomab not only prolonged the puncture-free interval but also showed a systemic effect in a patient with metastasized colorectal cancer by regression of a pulmonary metastasis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 30% |
| Student > Bachelor | 5 | 17% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Master | 4 | 13% |
| Other | 3 | 10% |
| Other | 1 | 3% |
| Unknown | 4 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 50% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Nursing and Health Professions | 2 | 7% |
| Agricultural and Biological Sciences | 2 | 7% |
| Immunology and Microbiology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 7 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 August 2021.
All research outputs
#6,266,826
of 22,738,543 outputs
Outputs from BMC Cancer
#1,563
of 8,272 outputs
Outputs of similar age
#74,080
of 304,442 outputs
Outputs of similar age from BMC Cancer
#16
of 100 outputs
Altmetric has tracked 22,738,543 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 8,272 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,442 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.